National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, Chinese Academy of Medical Sciences, China-Japan Friendship Hospital, No 2, East Yinghua Road, 100029, Beijing, China.
Department of Pulmonary and Critical Care Medicine, Affiliated Hospital of Jianghan University, No.168 Hongkong Road, 430000, Wuhan, Hubei, China.
BMC Pulm Med. 2024 Aug 28;24(1):417. doi: 10.1186/s12890-024-03225-0.
Hemoptysis resulting from rupture of the pulmonary artery pseudoaneurysm (PAP) is massive and fatal, while factor contributing to the rupture of pseudoaneurysm remains elusive. This study aimed to elucidate the clinical and radiological features of PAP and identify the risk factors associated with rupture.
Patients who developed hemoptysis with PAP were collected from January 2019 to December 2022 retrospectively. Clinical data of the demographic characteristics, radiological findings, treatment strategies, and prognosis were collected. A comparative analysis was performed on the characteristics in the ruptured and non-ruptured cases.
A total of 58 PAPs were identified in the 50 patients. The most common causes were infection (86%) and cancer (8%). The PAPs were located predominantly in the upper lobes of both lungs, and 57 (99.3%) were distributed in the segmental or subsegmental pulmonary arteries. The median diameter was 6.1(4.3-8.7) mm. A total of 29 PAPs were identified adjacent to pulmonary cavitations, with the median diameter of the cavity being 18.9 (12.4-34.8) mm. Rupture of pseudoaneurysm occurred in 21 cases (42%). Compared to unruptured group, the ruptured group had a significantly higher proportion of massive hemoptysis (57.1% vs. 6.9%, p < 0.001), larger pseudoaneurysm diameter (8.1 ± 3.2 mm vs. 6.0 ± 2.3 mm, p = 0.012), higher incidence of pulmonary cavitation (76.2% vs. 44.8%, p = 0.027), and larger cavitation diameters (32.9 ± 18.8 mm vs. 15.7 ± 8.4 mm, p = 0.005). The mean pulmonary artery pressure (mPAP) in the ruptured group was also significantly higher than that in the unruptured group [23.9 ± 7.4 mmHg vs. 19.2 ± 5.0 mmHg, p = 0.011]. Endovascular treatment was successfully performed in all 21 patients with ruptured PAP, of which the clinical success rate was 96.0%. Five patients experienced recurrent hemoptysis within one year.
Massive hemoptysis, pseudoaneurysm diameter, pulmonary cavitation, and elevated mPAP were the risk factors for rupture of pseudoaneurysm. Our findings facilitate early identification and timely intervention of PAP at high risk of rupture.
由肺动脉假性动脉瘤(PAP)破裂引起的咯血大量且致命,而导致假性动脉瘤破裂的因素仍不清楚。本研究旨在阐明 PAP 的临床和影像学特征,并确定与破裂相关的危险因素。
回顾性收集 2019 年 1 月至 2022 年 12 月期间因 PAP 咯血的患者。收集人口统计学特征、影像学发现、治疗策略和预后的临床数据。对破裂组和未破裂组的特征进行了比较分析。
在 50 例患者中,共发现 58 个 PAP。最常见的病因是感染(86%)和癌症(8%)。PAP 主要位于双肺上叶,57 个(99.3%)位于段或亚段肺动脉内。中位直径为 6.1(4.3-8.7)mm。共有 29 个 PAP 紧邻肺空洞,空洞中位直径为 18.9(12.4-34.8)mm。假性动脉瘤破裂发生在 21 例(42%)中。与未破裂组相比,破裂组大量咯血的比例明显更高(57.1%比 6.9%,p<0.001),假性动脉瘤直径更大(8.1±3.2mm比 6.0±2.3mm,p=0.012),肺空洞发生率更高(76.2%比 44.8%,p=0.027),空洞直径更大(32.9±18.8mm比 15.7±8.4mm,p=0.005)。破裂组平均肺动脉压(mPAP)也明显高于未破裂组[23.9±7.4mmHg 比 19.2±5.0mmHg,p=0.011]。21 例破裂 PAP 患者均成功进行了血管内治疗,其中临床成功率为 96.0%。5 例患者在 1 年内复发咯血。
大量咯血、假性动脉瘤直径、肺空洞和升高的 mPAP 是假性动脉瘤破裂的危险因素。我们的研究结果有助于早期识别和及时干预高危破裂的 PAP。